Margaux J. Hall

3 weeks ago | jdsupra.com | Sarah Barth |Margaux J. Hall

IntroductionOn May 12, 2025, President Trump issued an executive order (the “Executive Order”) directing executive agencies and, imminently, pharmaceutical manufacturers to take steps to deliver most-favored-nation (“MFN”) prescription drug pricing to patients in the United States.1 This Alert provides an overview of the Executive Order and potential related future agency action.

3 weeks ago | today.westlaw.com | Margaux J. Hall |Sarah Barth

The Executive Order focuses on global differentials in drug pricing, noting that the United States has front-loaded the costs of global innovation, with foreign countries' health systems getting a "free ride." The stated purpose of the Executive Order is to stop American patients from paying higher prices for pharmaceutical products sold at lower prices in other countries. The Executive Order thematically builds upon MFN policy initiatives advanced by President Trump in his first term.